NCT00130702View on ClinicalTrials.gov

Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Myelogenous Leukemia, Acute
Interventions
DRUG

gefitinib

gefitinib (Iressa) at a dose of 750 mg, once per day

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Boston Children's Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00130702 - Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia | Biotech Hunter | Biotech Hunter